DK1192247T3 - Sphingosinkinaseenzym - Google Patents

Sphingosinkinaseenzym

Info

Publication number: DK1192247T3
Authority: DK; Denmark
Prior art keywords: present; mimetics; analogues; derivatives; sphingosine kinase
Prior art date: 1999-05-13

Application number

DK00926537T

Other languages

Danish (da)

English (en)

Inventor

Stuart Maxwell Pitson

Brian Wolff Wattenberg

Pu Xia

Andrea Richard James D

Jennifer Ruth Gamble

Mathew Alexander Vadas

Original Assignee

Johnson & Johnson Pharm Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2000-05-12

Publication date

2006-07-31

1999-05-13 Priority claimed from AUPQ0339A external-priority patent/AUPQ033999A0/en

1999-07-08 Priority claimed from AUPQ1504A external-priority patent/AUPQ150499A0/en

2000-05-12 Application filed by Johnson & Johnson Pharm Res filed Critical Johnson & Johnson Pharm Res

2006-07-31 Application granted granted Critical

2006-07-31 Publication of DK1192247T3 publication Critical patent/DK1192247T3/da

Links

108010035597 sphingosine kinase Proteins 0.000 title abstract 2
230000001413 cellular effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 abstract 1
230000002068 genetic effect Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK00926537T 1999-05-13 2000-05-12 Sphingosinkinaseenzym DK1192247T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPQ0339A AUPQ033999A0 (en)	1999-05-13	1999-05-13	Novel therapeutic molecules and uses thereof
AUPQ1504A AUPQ150499A0 (en)	1999-07-08	1999-07-08	Novel therapeutic molecules and uses thereof-II

Publications (1)

Publication Number	Publication Date
DK1192247T3 true DK1192247T3 (da)	2006-07-31

Family

ID=25646054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00926537T DK1192247T3 (da)	1999-05-13	2000-05-12	Sphingosinkinaseenzym

Country Status (11)

Country	Link
US (3)	US6730480B1 (de)
EP (1)	EP1192247B9 (de)
JP (1)	JP2002543831A (de)
KR (1)	KR100798375B1 (de)
AT (1)	ATE323153T1 (de)
CA (1)	CA2372541A1 (de)
DE (1)	DE60027295T2 (de)
DK (1)	DK1192247T3 (de)
ES (1)	ES2261200T3 (de)
NZ (1)	NZ515132A (de)
WO (1)	WO2000070028A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6649362B2 (en) *	1997-09-08	2003-11-18	Medvet Science Pty. Ltd.	Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6423527B1 (en)	1997-09-29	2002-07-23	Children's Hospital Medical Center Of Northern California	Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
WO2001031029A2 (en) *	1999-10-28	2001-05-03	Warner-Lambert Company	Human sphingosine kinase gene
AU3828301A (en) *	2000-02-14	2001-08-27	Curagen Corp	Novel sphingosine kinases
AUPQ744700A0 (en) *	2000-05-11	2000-06-01	Medvet Science Pty. Ltd.	A method of treatment and agents useful for same
JP2004500903A (ja) *	2000-06-28	2004-01-15	メドベット・サイエンス・プロプライエタリー・リミテッド	治療的分子変種およびその使用方法
US6610534B2 (en)	2000-10-05	2003-08-26	Novartis Ag	Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
US6881546B2 (en)	2000-12-22	2005-04-19	Medlyte, Inc., Sdsu Heart Institute	Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
NZ529983A (en) *	2001-06-07	2006-09-29	Medvet Science Pty Ltd	Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
US7674580B2 (en)	2002-01-17	2010-03-09	Children's Hospital & Research Center At Oakland	Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
JP4667749B2 (ja) *	2002-01-17	2011-04-13	チルドレンズホスピタルアンドリサーチセンターアットオークランド	スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
CA2480661A1 (en) *	2002-03-28	2003-10-09	Medvet Science Pty. Ltd.	A method of modulating cellular activity
JP2006514828A (ja) *	2002-10-14	2006-05-18	メドベット・サイエンス・プロプライエタリー・リミテッド	スフィンゴシンキナーゼの機能的レベルを調節することによって上皮細胞活性を調節する方法
US20080050832A1 (en) *	2004-12-23	2008-02-28	Buechler Kenneth F	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060270631A1 (en) *	2005-05-26	2006-11-30	Smith Charles D	Methods for the treatment and prevention of angiogenic diseases
CA2624569A1 (en) *	2005-10-03	2007-04-12	Biosite Incorporated	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US9217749B2 (en)	2006-05-31	2015-12-22	Lpath, Inc.	Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2008070344A2 (en)	2006-10-27	2008-06-12	Lpath, Inc.	Compositions and methods for binding sphingosine-1-phosphate
US8221995B2 (en) *	2007-03-23	2012-07-17	Seok-Won Lee	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) *	2007-03-23	2009-01-01	Biosite, Incorporated	Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8778614B2 (en)	2010-08-24	2014-07-15	Enzo Life Sciences, Inc.	Assays for detecting modified compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1039801A4 (de) *	1997-06-06	2003-03-26	Human Genome Sciences Inc	207 menschliche sekretierte proteine
US6525174B1 (en) *	1997-06-06	2003-02-25	Human Genome Sciences, Inc.	Precerebellin-like protein
AUPO900297A0 (en) *	1997-09-08	1997-10-02	Medvet Science Pty. Ltd.	A method of modulating cellular activity
CA2329124A1 (en)	1998-05-26	1999-12-02	Office Of The Dean Of Research And Graduate Education	Sphingosine kinase, cloning, expression and methods of use
GB9816030D0 (en) *	1998-07-22	1998-09-23	Smithkline Beecham Plc	Novel compounds
AU2899900A (en) *	1999-03-02	2000-09-21	Nps Allelix Corp.	Cloned human sphingosine kinase homologues
AU3899600A (en) *	1999-03-18	2000-10-04	Incyte Pharmaceuticals, Inc.	Regulators of intracellular phosphorylation
US6610534B2 (en) *	2000-10-05	2003-08-26	Novartis Ag	Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases

2000
- 2000-05-12 AT AT00926537T patent/ATE323153T1/de active
- 2000-05-12 CA CA002372541A patent/CA2372541A1/en not_active Abandoned
- 2000-05-12 DK DK00926537T patent/DK1192247T3/da active
- 2000-05-12 EP EP00926537A patent/EP1192247B9/de not_active Expired - Lifetime
- 2000-05-12 KR KR1020017014462A patent/KR100798375B1/ko not_active Expired - Fee Related
- 2000-05-12 JP JP2000618434A patent/JP2002543831A/ja active Pending
- 2000-05-12 WO PCT/AU2000/000457 patent/WO2000070028A1/en not_active Ceased
- 2000-05-12 ES ES00926537T patent/ES2261200T3/es not_active Expired - Lifetime
- 2000-05-12 US US09/959,897 patent/US6730480B1/en not_active Expired - Lifetime
- 2000-05-12 DE DE60027295T patent/DE60027295T2/de not_active Expired - Lifetime
- 2000-05-12 NZ NZ515132A patent/NZ515132A/en not_active IP Right Cessation
2003
- 2003-08-18 US US10/642,289 patent/US7112427B2/en not_active Expired - Lifetime
2006
- 2006-09-26 US US11/526,708 patent/US20070071752A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1192247A4 (de)	2003-05-28
WO2000070028A1 (en)	2000-11-23
EP1192247B1 (de)	2006-04-12
EP1192247A1 (de)	2002-04-03
NZ515132A (en)	2005-01-28
US20040132053A1 (en)	2004-07-08
US20070071752A1 (en)	2007-03-29
JP2002543831A (ja)	2002-12-24
DE60027295T2 (de)	2007-01-18
ATE323153T1 (de)	2006-04-15
EP1192247B9 (de)	2007-10-31
CA2372541A1 (en)	2000-11-23
KR20020000805A (ko)	2002-01-05
ES2261200T3 (es)	2006-11-16
US6730480B1 (en)	2004-05-04
KR100798375B1 (ko)	2008-01-28
DE60027295D1 (de)	2006-05-24
US7112427B2 (en)	2006-09-26

Publication	Publication Date	Title
DE60027295D1 (de)	2006-05-24	Sphingosinekinase
DK0910647T3 (da)	2008-07-21	Human DNase i hyperaktive varianter
ATE286053T1 (de)	2005-01-15	Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
YU9404A (sh)	2006-08-17	Multimerna, usmerena kontrastna sredstva na bazi peptida
PL377553A1 (pl)	2006-02-06	Peptydy oraz pokrewne cząsteczki modulujące aktywność czynnika wzrostu nerwów
HUP0401124A2 (hu)	2004-08-30	VII koagulációs faktor származékok
AU2003266214A1 (en)	2004-04-19	Human coagulation factor vii polypeptides
TW200407425A (en)	2004-05-16	Human coagulation factor VII polypeptides
DE60137978D1 (de)	2009-04-23	Zusammensetzung zur förderung des haarwachstums
EP1100815A4 (de)	2005-05-25	Von protease typ ii spaltbares peptid
ATE294236T1 (de)	2005-05-15	Promotor der tie rezeptor protein kinase
ATE318328T1 (de)	2006-03-15	Diagnostika und therapeutika für osteoporose
ATE310085T1 (de)	2005-12-15	Cyclin-e2 proteine und dafür kodierende gene
ATE340257T1 (de)	2006-10-15	Histonedeacetylase 9
IL149416A0 (en)	2002-11-10	Human enzymes of the metalloprotease family
ATE356212T1 (de)	2007-03-15	O-fukosyltransferase
DK1339853T3 (da)	2006-11-13	Isolerede luciferaser og deres anvendelse
DE69535232D1 (de)	2006-11-02	DNA-SEQUENZEN, DIE FÜR DIE MENSCHLICHE PROTEINE Tx UND Ty KODIEREN, DIE ICE GLEICHEN
WO2002004521A3 (en)	2002-10-24	Proteins with integrin-like activity
MXPA02007787A (es)	2004-09-10	Moleculas trade y uso relacionado con las mismas.
BG101846A (bg)	1998-07-31	Варианти на човешка дезоксирибонуклеаза i
ATE328082T1 (de)	2006-06-15	Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1383908A4 (de)	2005-06-22	Isolierte menschliche enzymproteine, menschliche enzymproteine codierende nukleinsäuremoleküle sowie verwendungen davon
WO2003012102A3 (fr)	2004-04-08	Acides nucleiques codant des proteines a domaine hect
AU2002254438A1 (en)	2002-10-15	Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof